A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2020-07-04
عنوان الدراسة
A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
داعم الدراسة
AstraZeneca
دواء الدراسة
Osimertinib (AZD9291)
رقم بروتوكول الدراسة
D5160C00007
حالة الدراسة
Terminated
موقع الدراسة
King Faisal Specialist Hospital and Research Center (Riyadh)
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.